Insulin for All Act of 2023

Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to surprise billing law and regulation; Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations; Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; Issues related to removing barriers to biosimilar medicine access; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program; Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023; Issues related to mental health coverage, workforce, and mental health parity. S. 5093, Behavioral Health Network and Directory Improvement Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; Issues relating to S. 464/ H.R. 2630, the Safe Step Act; related amendment to S. 1339, the Pharmacy Benefit Manager Reform Act; H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023; S. 2840, Bipartisan Primary Care and Health Workforce Act and issues related commercial insurance, telehealth, and pharmacy benefits; H.R. 1843/S. 1001, the Telehealth Expansion Act of 2023 and related issues; S. 3393 Support for Patients and Communities Reauthorization Act; Issues related to artificial intelligence and health care issues; Issues related to P.L. 93-406, Employee Retirement Income Security Act of 1974 (ERISA), preemption.

Issues related to surprise billing law and regulation. Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. Issues related to removing barriers to biosimilar medicine access. Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program. Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023. Issues related to mental health coverage, workforce, and mental health parity. Behavioral Health Network and Directory Improvement Act. S. 1001, Issues related to the Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 1843, the Telehealth Expansion Act of 2023. H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues relating to S. 464/ H.R. 2630, the Safe Step Act; related amendment to S. 1339, the Pharmacy Benefit Manager Reform Act. H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023. S. 2840, Bipartisan Primary Care and Health Workforce Act and issues related commercial insurance, telehealth, and pharmacy benefits.

Educate policymakers on pharmacy issues related to TRICARE and H.R.2670, S.2226 Fiscal Year 2024 National Defense Authorization Act; issues related to P.L 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations; issues related to P.L 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; issues related to removing barriers to biosimilar medicine access; issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, INSULIN Act of 2023; S. 146, Cap Insulin Prices Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; issues related to mental health coverage, workforce, and mental health parity and the Behavioral Health Network and Directory Improvement Act and S. 2840, Bipartisan Primary Care and Health Workforce Act; and issues related commercial insurance, telehealth, and pharmacy benefits.

Client expense: Not reported · Firm income: $90,000

Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).

Client expense: $72,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to surprise billing law and regulation. Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. Issues related to removing barriers to biosimilar medicine access. Issues related to Quality-Adjusted Life Year (QALY) or similar metrics in health coverage legislation. Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program. Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S. 1542, the Delinking Revenue from Unfair Gouging Act (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, the PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. H.R. 2813, Self-Insurance Protection Act. Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S. 954, Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; H.R. 1485, Insulin for all Act of 2023. Issues related to mental health coverage, workforce, and mental health parity. Behavioral Health Network and Directory Improvement Act. S. 1001, Issues related to the Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 1843, the Telehealth Expansion Act of 2023. H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues relating to H.R. 3799, Custom Health Option and Individual Care Expense Arrangement Act (the CHOICE Arrangement Act). Issues relating to S. 464 / H.R. 2630, the Safe Step Act; related amendment to S. 1339.

Bayh-Dole march-in & royalty-free rights; IRA drug price negotiation implementation; Affordable Insulin Now Act (S.954); Insulin for All Act (S.727, H.R.1485); S. 1246 SMART Prices Act; Lowering Drug Costs for Families Act (S. 1139), IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines; Bayh-Dole march-in & royalty-free rights, U.S. government support for the mRNA Hub program, H.R. 1613 (Drug Price Transparency in Medicaid Act), S.1269 INSULIN Act, S.1067 Ensuring Timely Access to Generics Act; S. 1114 Expanding Access to Low-Cost Generics Act; S.1214 RARE Act; S.1339, Pharmacy Benefit Manager Reform Act, S.150; S.148; S.142; S.113; S.79; S.727; S.954; H.R.1488; S.1269; S.1067; S.1114; S.1339; S.775; S.1128; S.574; S.935; S.127, H.R. 2666 (MVP Act); Bayh-Dole march-in & royalty-free rights; government use patent licensing; NIH nomination; Affordable Drug Manufacturing Act; S.1476 (Pharmaceutical Research Transparency Act).

Client expense: $72,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to prescription drug pricing, particularly as it relates to insulin S. 146 - Cap Insulin Prices Act HR 1488/S. 954 - Affordable Insulin Now Act H.R. 1485 - Insulin for All Act of 2023 H.R.1587 - Making Insulin Affordable for All Children Act Issues related to the Special Diabetes Program renewal

Client expense: $330,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Health Worker Shortage/Staffing Crisis Green New Deal for Health, Entirety S.1113, Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act H.R.1485/S.727, Insulin for All Act H.R.1692, Health Care Affordability Act S.1139 A bill to apply prescription drug inflation rebates to drugs furnished in the commercial market Minimum staffing levels in skilled nursing facilities related issues Appropriations regarding but not limited to community violence intervention, the CDCs Office on Smoking and Health (OSH), School-Based Mental Health Services Professional Demonstration Grants/ School-Based Mental Health Services Grant Program and removing abortion prohibition language from future appropriations bills. Monitor the following: Public Law 117-169, Inflation Reduction Act, Prescription drug reform Public Law 117-159, Bipartisan Safer Communities Act Medicaid DSH Payments, Hospital funding formula Abortion Access related issues Supporting Trauma Informed Education Practices Act Restoring Hope for Mental Health and Well‐Being Act Nurse Overtime and Patient Safety Act Health Force and Resilience Force Act, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues The National Nurse Act, Entirety Telehealth issues Medicare X Choice Act Rural Healthcare related issues and initiatives H.R.12/S.701, the Women's Health Protection Act, Entirety Mental health supports for educators Closing Health Coverage Gaps for Public Servants Act Workplace Violence Prevention for Health Care and Social Service Worker Act Kids Online Safety Act Visas for international healthcare professionals Dobbs vs Jackson, United States Supreme Court decision Workplace violence related issues

Insulin for All Act of 2023 (H.R. 1485/S. 727); Affordable Insulin Now Act of 2023 (S. 954)

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Affordable Care Act, Extending ARPA Subsidies, Individual Market Reform, Behavioral Health (S. 923), Health Equity, Maternal Health, Implementation of No Surprises Act, Health IT, Interoperability, Value-Based Care, Health Care Innovation, COVID-19 PHE Transition (Medicaid Redeterminations, Commercialization of COVID-19 Vaccines & Therapeutics), HIPAA and Privacy, Telehealth, Public Option, Pharmacy Benefit Managers (S. 113, S. 127), Insulin Affordability (S. 146, S. 954, S. 727, H.R. 1485), Transparency (H.R. 410, S. 1130), Affordability (site neutral payment policies)

Client expense: $590,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE